19q 1914
2-(4-aminophenyl)benzothiazole 470
2-(4-aminophenyl)benzothiazoles 599
5′-deoxyfluorouridine 957
5-fluorouracil 957, 1507
5-FU 624, 1669
5HT3 antagonists 1823
5q21 region 1925
7q31 1909
7q31 region 1925
8p21 270
α1-adrenoceptor antagonists 1615
α5β1 integrin 327
α-fetoprotein 1878
α-particle emitter 213Bi 944
A33 antibody 937
acrylamide 84
adaptive intrapatient dose adjustment 814
additivism 1281
adenocarcinoma 63, 1229
adenocarcinoma of the cardia 401
adenoma size 1866
adenoma–carcinoma 1866
adenomatous polyposis coli (APC) 202
adenovirus 1492
adhesion molecules 1773
adrenal gland 1747
advanced non-small-cell lung cancer 342
adverse drug reaction 1157
adverse effects 1510
Africa 1
age 487, 839
agmatine 613
ALA derivatives (ALA hexyl ester) 432
alcohol 1044, 1702
alcohol drinking 58, 366
alcoholism 1044
alkylating agents 1828
alternative splicing 918
AMD473 1128
amelanotic melanoma 1462
amifostine 754
aminolevulinic acid (ALA) 432
anaemia 988, 1851
anal cancer 1352
androgen-independent 822
anger 658
angiogenesis 163, 307, 478, 537, 553, 718, 796, 1424, 1453, 1484, 1727, 1894
angiogenesis inhibitors 965
angiogenic factor 307
Annexin V 1301
antiapoptosis 902
antibiotics 1012
antibody directed enzyme-producing therapy (ADEPT) 937
antibody pretargeting 996
anticancer effect 1948
Antiemetics 1823
antineoplastic agents 1794
antioxidants 940, 1381
antitumoral agents 940
antivascular 1844
anti-VEGF mAb 1979
anxiety 658
Apaf-1 1786
APC 1932
apheresis 396
aponecrosis 1987
apoptosis 123, 161, 163, 210, 223, 298, 487, 586, 748, 754, 788, 910, 918, 1077, 1143, 1301, 1527, 1584, 1615, 1649, 1764, 1786, 1948, 1971
apoptosis induction 1801
areca 366
arginase 613
arginine 613
arginine decarboxylase 613
aromatase 630
aryl hydrocarbon receptor 599
association 1920
atrophic gastritis 1239
augmentation 832
autocrine 567
autophagy 1277
axillary nodes 104
Axin 1735
β-catenin 206, 1756
β-catenin 740
B7.1 424
B7.2 424
bak 1584
Barrett's oesophagus 1271
BAX 586, 848
BCL-2 848
Bcl-XL 910
Belgium 560
benign prostate hyperplasia 928
bereavement 1698
bilateral testicular neoplasms 828
bile acids 748
biochemotherapy 424
biological markers 1721
biomarkers 1239, 1271
bisphosphonates 1631, 1971
black gold miners 1361
bladder cancer 92, 586, 1492, 1932
bleomycin 1764
blood supply 291
blood vessel invasion 1894
BMI 36
BNIP3L 270
body mass 1038
body mass index 1388
body weight 679
bone infiltration 1105
bone marrow 855
bone metastasis 195, 1318
bone resorption 1318
bone scan 195
bone sialoprotein 396
bosentan 788
Bowen's disease 1375
BRAF 1403
brain tumours 1889
BRCA1 1256, 1285
BRCA1-defective cells 1285
BRCA1 protein 1263
BRCA2 933, 1256
breast 362, 702, 1339
breast and prostate cancer 438
breast cancer 50, 58, 133, 277, 406, 470, 491, 574, 630, 832, 863, 871, 944, 1047, 1065, 1077, 1084, 1091, 1168, 1207, 1256, 1310, 1318, 1358, 1400, 1587, 1708, 1894
breast cancer diagnosis 832
breast cancer resistance protein 878
breast cancer risk 1394
breastfeeding 1035
breast hereditary cancer 1285
breast imaging 4
breast implants 832
breast neoplasms 102, 832
breast self-examination 1047
breast tumours 579
bromodeoxyuridine 895
Burkitt's lymphoma 1566
butyrate 748
bystander effect 767
c-fos 1143
c-kit 1157
c-myc 1143
C4.4a 579
CA-19-9 1248
calcitonin 1537
cancer 163, 223, 270, 684
cancer immunotherapy 1292
cancer registries 1693
cancer susceptibility 487
cancer therapy 613
capecitabine 782
CAR 1411
carbonic anhydrase 1065
carcinogenesis 733, 740, 1217, 1501, 1735
carcinoma 702, 1543
carcinosarcoma 654
cardiotoxicity 1507
carotenoid 1381
case–control 58
case–control studies 373, 1702
caspase-3 1615
caspase-8 1527
caspase-9 1971
caspase-activated DNase 210
caspases 910, 1801
catabolism 613
caveolin-1 1234
CCR2 855
CD24 231
CD26/DPPIV 455
CD34 selection 1874
CD40 1527
CD40L 586
CDH1 1932
CDKN2A 1920
CEA 1248
cell cycle 455, 1417, 1470, 1649
cell cycle arrest 388, 754
cell death 613
cell death assays 125
cell invasion 1111
cell nucleolus 1942
cell proliferation 775
cervical cancer 1054, 1095, 1213, 1388, 1584
cervical cancer screening 560, 1570
cervical carcinoma 63
cervical screening 42
cervix cancer 1713
CGH 1578
chemokines 855, 1773
chemoradiation 1352
chemoradiotherapy 17
chemoresistance 624
chemotherapy 25, 167, 181, 187, 491, 496, 654, 1025, 1084, 1180, 1185, 1199, 1248, 1352
Child Health Questionnaire 1185
childhood cancer 373, 382, 1035, 1661
childhood leukaemia 775, 1939
childhood solid tumours 1370
children 1693
chimeric 1119
chimeric receptor 1292
CHO-K1 327
cholecystectomy 79
chromogranin 1747
chromosome 9 1578
chromosome aberrations 548, 1939
chronic disease 1851
chronic lymphatic leukaemia 74
chronic lymphocytic leukaemia 593
circumferential resection margin 1017
cirrhosis 733
CISH 1587
cisplatin 33, 814, 951, 1199, 1285, 1516
cisplatin-resistance 1327
citrulline 613
clear cell ovarian 1578
clinical trials 1128, 1661
CML 983
cohort study 684
collagen crosslinks 1105
collateral sensitivity 1963
collusion 839
colon 895
colon adenoma cancer 748
colon adenomas 79
colon cancer 79, 530, 788, 1445, 1756
colon carcinoma 937, 1995
colorectal 206
colorectal cancers 648, 1038, 1044, 1598, 1859, 1909
colorectal carcinoma 413, 726
combination chemotherapy 1942
comet assay 895
communication 666
communication skills 502, 658
comparative genomic hybridisation 1914
confocal microscopy 146
cost-effectiveness 31
costimulatory molecules 1527
coumarin derivatives 1111
COX-2 574, 1217, 1631
COX inhibitors 1143
CpG island 117, 413
CpG methylation 521
CPG2 1622
CPT-11 1979
crossreactivity 202
CXCR-4 1631
cyclin 1417
cyclin B1 257
cyclin D1 257
cyclin D2 1560
cyclin E 1914, 1956
cyclin-dependent kinase inhibitors 1277
cyclooxygenase-2 1445, 1598
cyclosporin 973
CYFRA 21-1 1894
CYP17 933
CYP1A1 599
CYP3A4 928
cystine 951
cytodiagnosis 1741
cytokines 630, 1207, 1773
cytological techniques 1883
cytology 702
cytology performance 1570
cytoprotection 754
cytoskeleton 1794
cytotoxic medium conditioning 447
Dacarbazine 132, 496
darbepoetin alpha 1851
decision making 1675
delayed reproductive death 548
deletion spectrum 90
demethylation 1560
denaturing HPLC 1889
de novo carcinoma 1866
deoxycytidine kinase 1963
depression 658
deprivation 613
detection 1358
DFF 210
DFF-B 210
DHPLC 270
diagnosis 354, 516, 839, 1175, 1239, 1358, 1878
diet 84, 1381, 1682
DMXAA 1160, 1844
DNA adducts 470
DNA damage 599
DNA fragmentation factor 210
DNA methylation 1932
DNA-ploidy 31
DNA repair 1939
DNA replication 895
DNA sequence 1403
docetaxel 11, 1168, 1335, 1339, 1669
documentation 839
dorsal root ganglion 1942
doxorubicin 1281, 1285, 1956
DPC4 420
drug resistance 775, 951, 973, 983, 1794, 1956
dwelling time 1866
dysadherin 726
dysphagia 18
dystroglycan 579
E-cadherin 1727
E-cadherin 718
E. tirucalli 1566
E1B-deleted 1492
early breast cancer 104
ECM 1470
EGF binding 1327
Egr-1 1143
electrochemotherapy 1764
electromagnetic fields 1939
electroporation 1764
endocrine tumours 1747
endogenous hormones 1394
endometrial cancer 1175
endometrial carcinoma 245
endometrial thickness 1175
endosomal/lysosomal acidification 1327
endothelial cells 307, 1484
endothelin 788
endothelin-1 163
Ep-CAM 574
epidemiology 63, 74, 382, 679, 684, 1032, 1370, 1682, 1687, 1698
epidermal growth factor 796
epithelial cancers 1501
epithelial ovarian carcinoma 237
Epstein–Barr virus 1566
ErbB2 396
erythropoietin 988, 1851
ethnicity 277
Etoposide 25, 140
Ewing's sarcoma 137
EWS 145
exercise 679
explant 767
extracellular matrix 871, 1248
extrahepatic bile duct carcinoma 1234
factors 988
familial 1256
Fas 1301
fascin 537
FasLigand 788
febrile neutropenia 181
FGF8b 1432
FHIT 1501
Fhit expression 1213
fibrin 718
fibulin 871
fine-needle aspiration 354, 699, 702
FISH 1432, 1587
Flanders 560
Fli-1 137
fluid-based specimen 1883
fluid-phase/receptor-mediated endocytosis 1327
fluoropyrimidines 648
fluorouracil 1017, 1510, 1859
folinic acid; adjuvant therapy 1859
food additives 940
formulation 50
Foscan® 146, 283
fotemustine 496
fragile sites 1501
fruit 1388
ftorafur 957
functional screening 910
fusion proteins 1622
γ-radiation 388
G1/S transition 1417
G2 arrest 1470
G2–M 455
gallstones 79
gastric cancer 796, 1909, 1914
gastric carcinoma 1560
gastrin-releasing peptide 1809
gastrointestinal tract 1747
gelsolin 606
gemcitabine 491, 1963
gene amplification 1587
gene expression profiles 1058
gene–gene interaction 928
gene therapy 1492
genetic counselling 1675
genetic markers 1741
genomic instability 548
genotoxic agents 298
glioblastoma multiforme 496, 516
glioma 463, 496, 1277, 1411, 1439
glutathione 951
Goseki classification 401
GPCR 567
growth factor 1522
GSK-3β 1470
GST genotypes 66
guidelines 1191
haem oxygenase 902
haematogenous dissemination 1894
haemodialysis 25
hAG-2 579
hAG-3 579
head and neck cancer 1012, 1217
head and neck carcinoma 1741
health-related quality of life 1185
health services 1025
Health Utilities Index 1185
height 1038
HeLa 613
HELG 1909
Helicobacter pylori 1239
hepatic stellate cells 733
hepatitis viral infection 521
hepatoblastoma 373
hepatocellular carcinoma 210, 521, 1878, 1909
hepatocytes 733
hepatoma 973
hepatoma-specific band of serum gamma-glutamyl transferase 1878
HER2 1032, 1587
HER-2/neu 1292
hereditary tumours 1285
hierarchical clustering 510
high-dose chemotherapy 1831, 1874
high-grade osteosarcoma 1925
hip implants 548
histidine triad 1501
histological type 1866
histology 843
HIT 1501
HMGI-C 1406
hMLH1 521
Hodgkin's disease 1335
Hoechst 33342 1979
homing 855
hormone factor risk 1032
hormone responsiveness 1071
HPV 251, 1213
HPV 16 serology 1095
HPV test performance 1570
HPV testing 42
hTERT 516
human 1721
human Mdm2 636
human neuroblastoma 1527
human papillomavirus (HPV) 63, 560, 1713, 1883
human sterol isomerase 438
Hybrid Capture II 1883
hyperammonia 447
hypermethylation 109, 1560
hyperthermia 1839
hypoxia 120, 307, 718, 1065, 1439
IAPs 1077
IDN 5390 965
ifosfamide 1168
IGF1 277
IGF-I 1682
IGFBP-3 1682
IκBα 624, 1615
IκB kinase-α 1598
IL-10 1605
IL-12 1453
IL-2 320
ILK 1470, 1756
image analysis 1439
image processing 1453
imatinib 983, 1157
immunocytochemistry 537
immunoglobulin gene 593
immunohistochemistry 231, 726, 1077, 1223, 1234, 1263, 1587, 1598, 1727, 1735
immunoreactivity 1432
immunostaining 257
immunotherapy 175, 348, 1135, 1346, 1641
in situ carcinoma 1375
in situ DNA synthesis 257
in vivo electropermeabilization 1764
independent prognostic factor 1406
induction 11, 1339
inflammation 1207, 1773
inflammatory breast cancer 718
iNOS 120
insulin 263
insulin-like growth factor-1 277
insulin-like growth factor-2 733
interleukin 6 630
interleukin-12 1641
interleukin-2 1641
interstitium 291
intracellular localisation 146
intrahepatic cholangiocarcinoma 1894
intrapleural therapy 1839
invasion 463, 1631
invasiveness factors 1207
ionising radiation 1786, 1801
irinotecan 335, 1180, 1516
ischaemia-reperfusion injury 760
isolated hepatic perfusion 314
Jak-STAT1 signalling 1995
Japanese 1038
Jurkat 455
Kaposi's sarcoma 1
kidney 327
kidney cancer 84
KOC 699
KRAB 137
kringles 1–5 1492
KSHV/HHV-8 1
Ku80 202
L1210 613
lactacystin 120
LAR 1223
large bowel cancer 84
lauryl gallate 940
LDB1 1543
leiomyosarcoma 510
leptomycin B 636
LIM 1543
limited proteolysis 636
linkage analysis 1920
lip cancer 1702
lipid droplets 1439
literature review 63
liver metastases 314
LMO4 1543
LOH 251, 270, 1578
long-term survival 496, 1666, 1894
loss of heterozygosity (LOH) 420, 1889
low-dose aspirin 684
lung cancer 606, 808, 1025, 1229, 1727
lung resistance-related protein 878
lymph node 553, 702
lymph node metastasis 237
lymphadenopathy 354
lymphodepletion 1874
lymphoma 140, 553
lymphopenia 181
macromolecule uptake 291
macrophage inhibitory factor-1 1101
magnetic resonance imaging 1017, 1135
magnetic resonance mammography 4
male and female breast cancer 933
malignancy 354
malignant fibrous histiocytoma 510
malignant melanoma 74, 175, 1358
malignant mesothelioma 1553
malignant neoplasms 362
malignant pleural mesothelioma 167
mammary carcinoma 1995
mammography 362
mannose 6-phosphate/insulin-like growth factor-2 receptor 733
MAP kinase 748
marker 1065, 1191
marker genes 1091
Markov model 1866
maspin gene expression 863
mast cells 1157
matrix metalloproteinases 1318, 1445, 1553
MCF-7 567, 599, 1310
MDA-MB-231 cell line 944
medullary thyroid cancer 1537
MEK 848
melanoma 132, 291, 424, 1157, 1381, 1403, 1920
melphalan 314
memory T cells 223
mesothelioma 1839
mesothelioma cells 388
meta-analysis 1047, 1191
metabolism 782
metastases 702
metastasis 96, 537
metastatic breast cancer 1406, 1631, 1669
metastatic colorectal cancer 1248
metastatic disease 491
methylation 217, 413, 463
MGMT 521
MHC II 424
microarray 510, 1995
microbeam 767
microcirculation 1462
microdialysis 782
microsatellite instability 413
microsatellite repeats 1741
microsatellites 1925
microspectrofluorometry 154
microtubules 1794
microvasculature 291
microvessel density (MVD) 314, 1424, 1900
midkine 1522
migration 1484
minichromosome maintenance (Mcm) proteins 257
mistletoe lectin 1786
mitogenesis 567
mitomycin 1516
mitosis 1649
mitotic cell death 1764
mitoxantrone 491
MMP-2 1248
molecular target 1522
monoclonal antibody 996
monocytes 1207
mortality 1047
mouse fibrosarcoma 760
MRI 478, 1592
mRNA 206
MtDNA 90
mucositis 1012
multicentre phase II study 1346
multidrug resistance 878, 1963
multidrug resistance-associated protein 1 878
multiple intestinal neoplasia 1445
multiple myeloma 855
multiple skin cancers 1375
multivariate analysis 1721
mutant p21 530
mutations 109, 206, 1271, 1403, 1584, 1909
N-cadherin 1727
N15 antibody 202
naïve T cells 223
napsin 1229
nasopharyngeal carcinoma 187
negative screening 1054
neoadjuvant 187, 1339
neoadjuvant chemotherapy 406, 1017
neoplasms 988, 1358
neoplastic cells 918
neovascularization 110
nervous system tumours 109
NESP55 1747
neuroblastoma 478, 1522, 1641, 1874
neurokinine receptor antagonists 1823
neuropilin 796
neurotoxicity 1942
nevus density 1920
NF-κB 120, 153, 624
nitric oxide 902, 1484
nitroimidazole 307
NK1 antagonists 1823
non-Hodgkin's lymphoma 74, 1335
nonplatinum regimen 342
non-small-cell lung cancer 231, 335, 537, 814, 1666
nonviral vectors 1641
normal prostate NPTX 1532 cells 1605
Northern Ireland 1256
NSAIDs 1687
nuclear factor-κB 1598
nuclear localisation 115
ODC 1143
oesophageal cancer 1549
oesophageal carcinoma 18, 1095
oesophageal squamous cell cancer 115
oesophageal squamous cell carcinoma 1217, 1735
oestrogen 50
oestrogen receptor 579, 871, 1071
oncological interviews 502
oral 648
oral contraceptives 50, 1713
oral leukoplakia 366
oral route 965
oral squamous cell carcinoma 1105
oral submucous fibrosis 366
ornithine 613
ornithine cycle 447
oropharyngeal carcinoma 1095
osteoclast 1318
osteosarcoma 396, 1995
ovarian cancer 470, 654, 666, 839, 848, 1781
ovary 1828
oxaliplatin 1942
oxidative stress 902
oxygen 1462
P-glycoprotein 878
P-subunit 1223
p14 217
p16 217
p21 protein 754
p21ras 1971
p27KIP1 1277
p53 251, 298, 636, 1281, 1310, 1492, 1649, 1786, 1925
p53 gene 1271, 1741
p53 protein 754
p63 740
paan chewing 1388
paclitaxel 1285, 1649, 1942
paediatric population 1925
PAI-1 96
pancreas 1747
pancreatic cancer 530, 679, 1180, 1971
pancreatic carcinoma 217
pancreatitis 217
parental smoking 373
pathology 654
patient 1119
patient information 1661
patient–physician relationship 658
pediatric 1185
penile carcinoma 1095
pepsinogen 1239
peptide vaccination 530
perfusion 291, 1439, 1979
perilesional skin 90
peripheral blood progenitor cell transplantation 1831
peritoneal cytology 245
PF regimens 11
pharmacodynamics 1160
pharmacokinetics 283, 782, 814, 1160, 1942
phase I 1128
phase I clinical trial 1844
phase I/II study 491
phase I study 1168
phase II 648
phenylacetate carboxymethyl benzylamide dextran (NaPaC) 1987
Phortress 470
phosphohistone H3 257
phosphoinositides 606
photodynamic diagnosis 1781
photodynamic therapy 283, 1773
photodynamic therapy (PDT) 432, 760
physical activity 679
physicians’ locus of control 502
PKC 606, 748
plasminogen 1492
plasminogen activation inhibitor type 2 944
platinum 1128
platinum DNA adducts 814
pleural malignancies 1839
PMN-elastase 1084
polymerase chain reaction 1883
polymorphism 263, 928
population-based cohort study 382
population mixing 1370
prediction 1091
predictive markers 406
predisposing 988
prevention 1687
primary cells 1071
primary liver carcinoma 1894
progestin 50
prognosis 18, 102, 237, 348, 516, 537, 574, 593, 726, 1065, 1191, 1549, 1553
prognostic factors 1199, 1510, 1537
prognostic indicator 1077
prognostic markers 31, 115, 586
prognostic value 401, 863
prolactin 1301
prolactin receptor 1301
proliferation 613, 767, 1143, 1484
proliferation inhibition 438
prophylactic mastectomy 1675
prophylaxis 1507
prospective study 1394
prostaglandin E2 630
prostate cancer 31, 195, 263, 822, 928, 1101, 1358, 1432, 1615, 1682
proteasome 636
protein 1417
protein induced by vitamin K absence or antagonist II 1878
protein kinase C alpha 1400
protein p53 1794
protein tyrosine kinase inhibitors 940
protein-tyrosine kinase 1058
proteolysis 871
protoporphyrin IX 1462
protracted intravenous infusion 1859
Pseudomonas exotoxin 1327
psychological stress 1698
psychosocial impact 42
PTHRP 567
PTP 1223
pyridinoline 1105
quality of life 988
quantitative RT–PCR 1101
quinazolines 1615
radiation 487
radiosensitivity 128, 1470
radiotherapy 187, 828, 1012, 1017, 1025, 1352, 1584
raltitrexed 1180
randomised phase III trial 335
rat fibroblasts 1956
RAY1 1909
Rb 1925
RB1 gene 109
real-time PCR 516, 1091
real-time RT–PCR quantification 863
receptor 1119
recombinant 988
recombinant fusion proteins 937
records 839
relapse-free survival 1537
relative risk 1054
renal-cell carcinoma (RCC) 348, 1346, 1417, 1516, 1801
renal insufficiency 25
repressor 137
resection margin 1549
residual neoplasms 843
response 424
response biomarker 1592
response to therapy 1084
retinoic acid 1058
retinol 1381
retrovirus 1119
RhoA 1631
risk 348, 684, 1687
risk factors 79, 181, 366, 1702
risk model 181
risk perception 1675
ruthenium(III) 1484
S-1 648
S-phase arrest 599
Sant 7 630
Scotland 1256
screening 1708
SDF-1 1631
seasonal variation 1358
second line 1828
second-line treatment 1180
self-efficacy 658
senescence, apoptosis 463
sequential-triplet chemotherapy 342
sex behaviour 666
sex ratio in offspring 382
sigma receptors 438
signal transduction 796, 1281
signal transduction pathways 1801
signalling 153
silicone 832
single nucleotide polymorphism 1735
skin cancer 98
Smad 1615
Smad4 420
smoking 366
soft tissue sarcoma 510
solid tumours 1831
soluble CD105 1424
somatic hypermutation 593
somatostatin 140
South Africa 1361
SP-G 1809
specialisation 1708
spectroscopy 478
spermatogonia 828
spheroid model 463
sporadic breast cancer 1263
squamous cell carcinoma 63
squamous cell carcinoma of the head and neck 11
SR31747A 438
ST7 1909
staging 1105
standardised incidence ratio 1666
standardised mortality ratio 1666
statistical methods 1693
statistical models 843
stratification 348
substance P 1823
substance P analogues 1809
sun exposure 1702
surfactant protein 1229
surgery 1025, 1549
survival 348, 1025, 1693, 1698, 1708
survival-analysis 102, 1191
survival rate 1721
survivin 1077
survivin expression 115
synovial sarcoma 510
synthesis 1948
systematic review 1191
T-cell homeostatic proliferation 1874
T-cells 530
T lymphocyte 1119
tamoxifen 1084, 1175
tamoxifen resistance 1400
tandem duplications 90
targeted α therapy 944
targeting 1622
taxanes 965, 1339
Taxol 973
TCF 1932
telomere length 593
temozolomide 175
tenascin 996
testicular biopsy 828
testicular cancer 36
testicular germ-cell tumours 878
testicular intraepithelial neoplasia 828
testicular neoplasms 828
testis 843
TGF-β1 1615
TGFβ 420, 1424
thalidomide 822
therapy 478
thymidine kinase 1963
thymidine phosphorylase 957
thymidine phosphorylase inhibitor 957
thyroid cancer 1358
thyroid carcinoma 1223
TIL 320
time course 1510
time-lapse microscopy 1310
TIMP-1 1248, 1605
tissue exposure 782
tissue microarray 231, 1417
TNF-α 314
tobacco 1702
tocopherol 1381
tomudex 624
topoisomerase I 1310
topoisomerase I inhibitor 808
topoisomerase II α 455
topoisomerase II inhibitor 808
topotecan 1310
toxicity 181, 1160, 1199, 1831
TP53 848
TRAIL 153, 298, 910, 918, 1801
TRAIL receptors 298
transport mechanisms 291
transporter 951
transvaginal ultrasonography 1175
treatment 36
trifluorothymidine 957
TT-232 140
TTF-1 1229
tumorigenesis 420
tumour angiogenesis 1987
tumour delivery 1979
tumour growth 163, 902, 1111, 1809
tumour immunosuppression 320
tumour marker 396, 699, 1522, 1894
tumour metastasis 327
tumour perfusion 1592
tumour response 406
tumour suppression 606
tumour suppressor 1411, 1501
tumour-suppressor gene 1909
tumour targeting 937
tumours 1119, 1135, 1462
tyrosine phosphorylation 1605
ultrasound 354, 702
uPA 96
urea/bisulphite sequencing 521
urinary sex steroids 1394
urothelium 740, 767
vaginal and vulvar cancer 1095
validity 843
vascular damage 283
vascular endothelial growth factor (VEGF) 796, 1987
vascular phenotype 553
vascular regression 553
vascular targeting agents 1592
vegetables 1388
VEGF 1622
VEGF-C 237
VEGF-D 237
VEGFR-3 237, 1453
VIN 251
vinorelbine 1281
viral gene expression 1566
visible reflectance spectroscopy 760
vitamin D receptor 928
vitamin E analogues 1948
vitamin E succinate 153
vulval cancer 251
vulval intraepithelial neoplasia (VIN) 257
warts 1702
weekly chemotherapy 808
women 1381
X-rays 447
xanthine oxidase 760
xenograft 478
ζ chain 223
ZD6126 1592
zoledronate 1971
zoledronic acid 1971
zometa 1971
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 88. Br J Cancer 89, 2350–2354 (2003). https://doi.org/10.1038/sj.bjc.6601555
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6601555